Recently, the Class 1 innovative drug Limertinib Tablets (trade name: 奥壹新) of Jiangsu Osaikang Pharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after previous treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) and have been confirmed by testing to carry the EGFR T790M mutation. The approval of this drug provides a new treatment option for this patient population.